The effect of teriparatide on serum Dickkopf-1 levels in postmenopausal women with established osteoporosis

被引:56
作者
Anastasilakis, Athanasios D. [1 ]
Polyzos, Stergios A. [2 ]
Avramidis, Avraam [3 ]
Toulis, Konstantinos A. [1 ]
Papatheodorou, Athanasios [4 ]
Terpos, Evangelos [4 ]
机构
[1] 424 Gen Mil Hosp, Dept Endocrinol, Thessaloniki, Greece
[2] Aristotle Univ Thessaloniki, Dept Internal Med 2, Hippokrat Gen Hosp, GR-54006 Thessaloniki, Greece
[3] Hippokrateion Hosp, Dept Endocrinol, Thessaloniki, Greece
[4] 251 Gen AF Hosp, Dept Med Res, Athens, Greece
关键词
BONE-MINERAL DENSITY; PARATHYROID-HORMONE; OSTEOBLAST DIFFERENTIATION; WNT; EXPRESSION; DKK-1; CELLS; GENE; ANTAGONISTS; SCLEROSTIN;
D O I
10.1111/j.1365-2265.2009.03728.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective Parathyroid hormone increases the differentiation of osteoblast precursors through canonical wingless (Wnt) signalling, resulting in an osteoanabolic effect. We aimed to evaluate serum levels of the Wnt-inhibitor Dickkopf-1 (Dkk-1) in postmenopausal women with established osteoporosis and their changes with teriparatide (TPTD-human recombinant PTH 1-34). Design and patients A total of 31 postmenopausal Caucasian women with established osteoporosis (mean age 66.3 +/- 1.4 years) received daily injections of 20 mu g TPTD for 18 months. Follow-up was continued for another 6 months after treatment discontinuation (total duration of treatment 24 months). Measurements Serum samples for total calcium (Ca), intact PTH (iPTH), bone-specific alkaline phosphatase, C-terminal cross-linking telopeptide of type 1 collagen (CTx) and Dkk-1 were obtained at baseline, and at 6, 18 and 24 months after TPTD initiation. Lumbar spine bone mineral density (BMD) was measured before and after 18 months of TPTD treatment. A total of 16 age-and gender-matched healthy controls were also analysed at baseline. Results Serum Dkk-1 levels at baseline were significantly higher in osteoporotic women compared with that in controls (P < 0 002). Dkk-1 increased significantly during TPTD administration (P < 0 044) and decreased to baseline 6 months after TPTD discontinuation. Dkk-1 change was positively correlated to Ca (r = 0.530, P = 0.004) and negatively correlated to iPTH change (r =-0.398, P = 0.040). There was no correlation between Dkk-1 and BMD changes. Conclusions Our data suggest that Dkk-1 levels are increased in women with postmenopausal osteoporosis. TPTD therapy results in further increase of Dkk-1 that may be compensative to TPTD-induced enhanced Wnt signalling.
引用
收藏
页码:752 / 757
页数:6
相关论文
共 38 条
[1]   The Wnt antagonist DICKKOPF-1 gene is induced by 1α,25-dihydroxyvitamin D3 associated to the differentiation of human colon cancer cells [J].
Aguilera, Oscar ;
Pena, Cristina ;
Miguel Garcia, Jose ;
Jesus Larriba, Maria ;
Ordonez-Moran, Paloma ;
Navarro, Diego ;
Barbachano, Antonio ;
Lopez de Silanes, Isabel ;
Ballestar, Esteban ;
Fraga, Mario F. ;
Esteller, Manel ;
Gamallo, Carlos ;
Bonilla, Felix ;
Manuel Gonzalez-Sancho, Jose ;
Munoz, Alberto .
CARCINOGENESIS, 2007, 28 (09) :1877-1884
[2]   Oxysterol-induced osteogenic differentiation of marrow stromal cells is regulated by Dkk-1 inhibitable and PI3-Kinase mediated signaling [J].
Amantea, Christopher M. ;
Kim, Woo-Kyun ;
Meliton, Vicente ;
Tetradis, Sotirios ;
Parhami, Farhad .
JOURNAL OF CELLULAR BIOCHEMISTRY, 2008, 105 (02) :424-436
[3]   Head-to-head comparison of risedronate vs. teriparatide on bone turnover markers in women with postmenopausal osteoporosis: a randomised trial [J].
Anastasilakis, A. D. ;
Goulis, D. G. ;
Polyzos, S. A. ;
Gerou, S. ;
Koukoulis, G. N. ;
Efstathiadou, Z. ;
Kita, M. ;
Avramidis, A. .
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2008, 62 (06) :919-924
[4]   Endogenous intact PTH is suppressed during teriparatide (rhPTH 1-34) administration in postmenopausal women with established osteoporosis [J].
Anastasilakis, Athanasios D. ;
Polyzos, Stergios A. ;
Goulis, Dimitrios G. ;
Slavakis, Aristides ;
Efstathiadou, Zoe ;
Kita, Marina ;
Koukoulis, George ;
Avramidis, Avraam .
ENDOCRINE JOURNAL, 2008, 55 (03) :613-616
[5]   Acute changes in serum osteoprotegerin and receptor activator for nuclear factor-κB ligand levels in women with established osteoporosis treated with teriparatide [J].
Anastasilakis, Athanasios D. ;
Goulis, Dimirtios G. ;
Polyzos, Stergios A. ;
Gerou, Spiridon ;
Pavlidou, Vasiliki ;
Koukoulis, George ;
Avramidis, Avraam .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2008, 158 (03) :411-415
[6]   Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: A novel mechanism for hormonal control of osteoblastogenesis [J].
Bellido, T ;
Ali, AA ;
Gubrij, I ;
Plotkin, LI ;
Fu, Q ;
O'Brien, CA ;
Manolagas, SC ;
Jilka, RL .
ENDOCRINOLOGY, 2005, 146 (11) :4577-4583
[7]   Bone anabolic effects of parathyroid hormone are blunted by deletion of the Wnt antagonist secreted frizzled-related protein-1 [J].
Bodine, Peter V. N. ;
Seestaller-Wehr, Laura ;
Kharode, Yogendra P. ;
Bex, Frederick J. ;
Komm, Barry S. .
JOURNAL OF CELLULAR PHYSIOLOGY, 2007, 210 (02) :352-357
[8]   A Randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis [J].
Body, JJ ;
Gaich, GA ;
Scheele, WH ;
Kulkarni, PM ;
Miller, PD ;
Peretz, A ;
Dore, RK ;
Correa-Rotter, R ;
Papaioannou, A ;
Cumming, DC ;
Hodsman, AB .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (10) :4528-4535
[9]   Bone morphogenetic proteins, their antagonists, and the skeleton [J].
Canalis, E ;
Economides, AN ;
Gazzerro, E .
ENDOCRINE REVIEWS, 2003, 24 (02) :218-235
[10]   Mechanisms of anabolic therapies for osteoporosis [J].
Canalis, Ernesto ;
Giustina, Andrea ;
Bilezikian, John P. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (09) :905-916